Payment & Shipping Terms:
|CAS:||53123-88-9||Alias:||Rapamycin , AY 22989|
|Apparence:||Almost White Crystalline Powder||Purity:||99.5%|
|Stock:||Enough Stock||Grade:||Pharma Grade|
Factory supply Rapamycin (AY 22989) Used as immunosuppressant 53123-88-9
Other Names: AY 22989;23,27-EPOXY-3H-PYRIDO(2,1-C)(1,4)OXAAZACYCLOHENTRIACONTINE;NSC-226080;RAPA;RAPAMUNE;RAPAMYCIN;RAPAMYCIN, STREPTOMYCES HYGROSCOPICUS;RPM
CAS No.: 53123-88-9
Molecular Formula: C51H79NO13
Molecular Weight: 914.18
Appearance: White or Nearly White Crystalline Powder
Manufacturer: Jusheng Factory
Rapamycin (sirolimus) is a kind of secondary metabolite produced by the soil streptomyces secretion firstly found in Chile Easter island soil in 1975, and its chemical structure belongs to "triene large ring lactone class" compounds. Due to the low rapamycin fermentation yield and complicated extraction process, until 1999, the product was developed and appeared in the market by American household chemicals company, and then gone public in a dozen countries in Europe and the United States. The U.S. food and drug administration (FDA) approved indications of rapamycin is not antibiotics but "immunosuppressant. This is because rapamycin showed a strong immunosuppressive effect in clinical trials, and can replace ring spore which has a clinical history more than 30 years. And compared with ring spore, the oral dose of rapamycin is smaller (only take 2~3 mg each time), anti-rejection effect is stronger, and less side effects. So since rapamycin listed, it was quickly used as common oral immune inhibitors for transplants in the world.
Targeted Cancer Therapy Drugs
In recent years, studies found that as an intracellular kinase, the pathway abnormality of rapamycin target protein (mTOR) may induce many diseases. Rapamycin as mTOR’s targeted inhibitor, can treat the tumors closely related to the pathway including kidney cancer, lymphoma, lung cancer, liver cancer, breast cancer, neuroendocrine carcinoma and gastric cancer, etc. Especially for LAM (lymphatic fibroid disease) and TSC tuberous sclerosis-the treatment effect of the two kinds of rare diseases is more apparent, and to some extent LAM and TSC can be considered as tumor diseases.
How to proceed order